Clinical trials
Relapsed or Refractory Large B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,746 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07778316RecruitingPhase 3
Tarlatamab for small cell lung cancer after first chemotherapy
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
Grand Rapids, MichiganAges 18–99 - NCT04474847RecruitingPhase 3
Abatacept for giant cell arteritis treatment
This Phase 3 trial tests abatacept to treat giant cell arteritis (GCA), a blood vessel inflammation that can cause headaches and vision risk. It’s for people with newly diagnosed or returning (relapsing) GCA with active symptoms in the last 8 weeks.
Rochester, MinnesotaAges 50 years+ - NCT05011422RecruitingPhase 1
Stem cell transplant using half-matched donor for kids with blood cancer
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
St Louis, MissouriAges Up to 30 years - NCT07104032RecruitingPhase 3
Tirabrutinib vs standard therapy for relapsed PCNSL
This study tests a new oral targeted drug called tirabrutinib against a standard treatment combination (rituximab plus temozolomide) for people whose primary central nervous system lymphoma has come back or not responded to prior therapy.
Phoenix, ArizonaAges 18 years+ - NCT06607549RecruitingPhase 1
Targeted drug combo after focused radiation for CNS lymphoma
This trial tests a combination of two targeted drugs (loncastuximab tesirine and rituximab) given after focused radiation (SRS) for people with CNS lymphoma that has come back or not responded to treatment, or who cannot get standard high-dose methotrexate. The goal is to see if this approach is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07751380RecruitingPhase 1
CAR T-cell therapy for children and young adults with certain sarcomas
This trial tests a new kind of cell therapy called CAR T-cells that are engineered to find and attack sarcoma cells carrying a marker called B7-H3. It is for children and young adults whose sarcoma has come back or not gone away after treatment.
LondonAges 1–24 - NCT06066359RecruitingPhase 1/Phase 2
Cord blood NK cells for NY-ESO-1 positive myeloma
This trial tests a new treatment using cord blood immune cells (NK cells) that are specially designed to target a protein called NY-ESO-1 found on myeloma cells. It is for people with multiple myeloma that has come back or not responded to at least two previous treatments.
Houston, TexasAges 18–80 - NCT07741825Recruiting
Mindfulness training to prevent relapse for peer support workers
This study tests a mindfulness-based program to help people who work as peer support specialists in substance use recovery reduce their risk of relapse. It may help you manage cravings and stay healthy in your role.
Austin, TexasAges 18–100 - NCT04715191RecruitingPhase 1
CAR T therapy for GPC3-positive pediatric solid tumors
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
Houston, TexasAges 1–21 - NCT06695013RecruitingPhase 2
Maintenance therapy after CAR-T for low-risk B-cell lymphoma
This study tests whether adding a type of maintenance therapy after CAR-T cell treatment helps people with low-risk B-cell lymphoma that has returned or not responded to standard treatments. It compares the standard CAR-T approach to one with extra immune-supporting treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06343792RecruitingPhase 2
Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Duarte, CaliforniaAges 12 years+ - NCT06021678RecruitingPhase 1/Phase 2
EX103 for relapsed or refractory CD20-positive lymphoma
This trial tests a new drug called EX103 for people whose non-Hodgkin lymphoma (a cancer of the immune system) has come back or not responded to earlier treatments. The goal is to see if EX103 is safe and can shrink tumors.
Zhengzhou, HenanAges 18 years+ - NCT05756322RecruitingPhase 1/Phase 2
Study medicine LBS-007 for relapsed leukemia patients
This trial tests how safe and tolerable LBS-007 is for adults with AML or ALL that has come back or is resistant to treatment. It may help people who can’t use standard therapies or have no proven treatment options.
Tampa, FloridaAges 18–120 - NCT05344469Recruiting
Testing new MS medicines in people with active relapsing MS
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
Albstadt, Baden-WurttembergAges 18–100 - NCT04237675Recruiting
Study of MS relapses after surgery
This study looks at relapses (new or worsening MS symptoms) after surgery in people with multiple sclerosis (MS). It may help researchers understand what triggers relapse after surgery so better care can be planned.
Athens, AtticaAges 18–70 - NCT03000244Recruiting
Long-term follow-up after stem cell or gene therapy
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
Bethesda, MarylandAges 4–120 - NCT02312830Enrolling by invitation
Study of long-term transplant survivors at one Belgian hospital
This study invites adults who had a donor (allogeneic) transplant at KU Leuven long ago to share health information during a scheduled checkup. It may help researchers better understand long-term outcomes and support needs after transplant.
Ages 18–100 - NCT05416775RecruitingPhase 1/Phase 2
Test drug SHR-8068 for advanced lung cancer
This trial tests SHR-8068 in people with advanced non-small cell lung cancer (NSCLC). It may help by controlling cancer after standard treatments have not worked, and it’s designed to find the right way to give the drug.
Hefei, AnhuiAges 18–75 - NCT06378892RecruitingPhase 2
Study of chemo plus lorlatinib for ALK+ lung cancer
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
AvianoAges 18 years+ - NCT06773091RecruitingPhase 1
NK cell therapy for advanced solid tumors
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
BeijingAges 18–70 - NCT07191431Recruiting
Study of drug combo for returning brain lymphoma
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 14–80 - NCT07161258RecruitingPhase 2
Fenebrutinib for children with relapsing MS
This study tests a new oral medication called fenebrutinib for children and teenagers with relapsing multiple sclerosis. It aims to find the right dose and see how safe and effective it is compared to standard treatments.
Rosario, Santa Fe ProvinceAges 10–17 - NCT06066424RecruitingPhase 1
TROP2-targeted NK cells for advanced solid tumors
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06658951Recruiting
HER2-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–70
Hear when a new Relapsed or Refractory Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory large b-cell lymphoma?
- Yes. Clin2 currently lists 1,746 recruiting relapsed or refractory large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed or Refractory B-cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.